Novartis wins US label for Cosentyx in polymyalgia rheumatica
The FDA clearance gives Novartis a new US indication for the 150 mg dose, though the company has not yet disclosed pricing, launch timing or trial data.
17 Nov 2026 · Novartis Pharma AG · Company news
Novartis has secured US regulatory clearance for a new use of Cosentyx (secukinumab), adding polymyalgia rheumatica (PMR) to the products' American label. The company announced the decision on 17 November 2026. The approval covers the 150 mg dose in adult patients.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More Approvals & launchesAll →
Approvals & launches
FDA approves Roche's Wilserdly with everolimus for ESR1-mutated advanced breast cancer
16 Nov 2026 · Roche · Company news
Approvals & launches
FDA approves Roche's oral SERD Wilserdly with everolimus for ESR1-mutated breast cancer
16 Nov 2026 · F. Hoffmann-La Roche Ltd · Company news
Approvals & launches
Larimar completes BLA submission for nomlabofusp in Friedreich's ataxia, seeking accelerated approval
16 Nov 2026 · Larimar Therapeutics, Inc. LRMR · Company news
Approvals & launches
FDA grants Breakthrough Therapy status to daretabart for newly diagnosed high-risk neuroblastoma in children
16 Nov 2026 · Essential Pharma · Company news
Approvals & launches
Lakefront Biotherapeutics launches second €50m share buyback after completing first programme
16 Nov 2026 · Lakefront Biotherapeutics · Company news
Approvals & launches
Imricor starts US launch of NorthStar iMR system after paediatric FDA clearances
13 Nov 2026 · Imricor Medical Systems, Inc. · Company news